MYGN Stock Recent News
MYGN LATEST HEADLINES
Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing
Myriad Genetics posted Q2 2025 revenue growth of 1% year-over-year, but adjusted for one-time events, growth would have been 5%. Key growth drivers include expanding Hereditary Cancer Testing to unaffected cancer patients and launching the Precise MRD test for molecular residual disease. Full-year 2025 revenue guidance was raised to $818-$828 million, reflecting confidence in continued growth and expanding total addressable markets.
Myriad Genetics, Inc. (NASDAQ:MYGN ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Mark S. Verratti - Chief Operating Officer Matthew Scalo - Senior Vice President of Investor Relations Samraat S.
Myriad Genetics (MYGN) Q2 Revenue Up 6%
The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Myriad Genetics (MYGN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to earnings of $0.05 per share a year ago.
Myriad Genetics announced financial results for its second quarter ended June 30, 2025, updated full-year 2025 financial guidance on business performance.
ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) complied with federal securities laws. On May 6, 2025, Myriad Genetics reported first quarter 2025 financial results, and lowered its 2025 financial guidance, revealing, among other things, a decline in pharmacogenomics revenue by 20% year-over-year “due to UnitedHealthcare (UNH) reduc[ing] coverage of GeneSight.” Following this news, the price of the Company's stock dropped.
MYGN sees growth in oncology and women's health testing, but GeneSight coverage loss clouds the near-term outlook.
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?